RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
CNS Pharmaceuticals Stock

CNS Pharmaceuticals ROE 2024

CNS Pharmaceuticals ROE

4.25

Ticker

CNSP

ISIN

US18978H1023

WKN

A2PNH4

In 2024, CNS Pharmaceuticals's return on equity (ROE) was 4.25, a -326.45% increase from the -1.88 ROE in the previous year.

CNS Pharmaceuticals Aktienanalyse

What does CNS Pharmaceuticals do?

CNS Pharmaceuticals Inc is an American pharmaceutical company specializing in the development and marketing of innovative therapies for patients with severe and life-threatening central nervous system disorders. The company was founded in 2017 and is headquartered in Houston, Texas. CNS Pharmaceuticals Inc's history began with the realization that there is an urgent need for new and more effective treatment methods for central nervous system tumors. The company's founders therefore identified promising new drugs based on the latest research findings and began testing them in clinical trials. CNS Pharmaceuticals Inc's business model focuses on innovative research and development of new drugs, as well as close collaboration with leading scientists and medical professional societies. The company aims to bring its medications to market quickly and cost-effectively, without compromising on quality or safety. The various divisions of CNS Pharmaceuticals Inc include research, development, production, and marketing of its drugs. The company has launched a variety of research projects aimed at developing new therapies for patients with brain tumors and other severe central nervous system disorders. One of CNS Pharmaceuticals Inc's most well-known products is Berubicin, a promising drug for the treatment of glioblastoma, a particularly aggressive type of brain tumor. Berubicin is a novel DNA-intercalating drug that is highly effective and has low toxicity. Clinical trials have already shown that Berubicin can extend the survival time of patients. Another important product of CNS Pharmaceuticals Inc is WP1244, a drug against glioblastoma based on an innovative technology that improves the uptake of drugs into cells. Preclinical studies have already shown that WP1244 is able to stop tumor growth and destroy cancer cells. CNS Pharmaceuticals Inc has a strong network of partner companies and distribution partners that help with the marketing and dissemination of its products. The company works closely with leading cancer centers and research institutions to further improve the effectiveness of its drugs and provide patients with a higher level of safety and quality of life. Overall, CNS Pharmaceuticals Inc has established itself as a dynamic and innovative company with a high level of expertise in the development of new drugs. The company aims to expand its position as a leading provider of therapies for patients with brain tumors and other severe central nervous system disorders, and to sustainably improve the quality of life of affected patients. CNS Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROE Details

Decoding CNS Pharmaceuticals's Return on Equity (ROE)

CNS Pharmaceuticals's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing CNS Pharmaceuticals's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

CNS Pharmaceuticals's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in CNS Pharmaceuticals’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about CNS Pharmaceuticals stock

What is the ROE (Return on Equity) of CNS Pharmaceuticals this year?

The ROE of CNS Pharmaceuticals this year is 4.25 undefined.

How has the Return on Equity (ROE) of CNS Pharmaceuticals developed compared to the previous year?

The ROE of CNS Pharmaceuticals has increased by -326.45% decreased compared to the previous year.

What impact does a high ROE (Return on Equity) have on investors of CNS Pharmaceuticals?

A high ROE indicates that CNS Pharmaceuticals generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.

What impact does a low ROE (Return on Equity) have on investors of CNS Pharmaceuticals?

A low ROE can indicate that CNS Pharmaceuticals is having difficulties monetizing its investments successfully and can be a negative signal for investors.

How does a change in the ROE (Return on Equity) of CNS Pharmaceuticals affect the company?

A change in ROE (Return on Equity) of CNS Pharmaceuticals can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.

How to calculate the ROE (Return on Equity) of CNS Pharmaceuticals?

The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.

Which factors influence the ROE (Return on Equity) of CNS Pharmaceuticals?

Some factors that can influence CNS Pharmaceuticals's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.

What strategic measures can take to improve the ROE (Return on Equity)?

To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.

How much dividend does CNS Pharmaceuticals pay?

Over the past 12 months, CNS Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, CNS Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of CNS Pharmaceuticals?

The current dividend yield of CNS Pharmaceuticals is .

When does CNS Pharmaceuticals pay dividends?

CNS Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of CNS Pharmaceuticals?

CNS Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of CNS Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is CNS Pharmaceuticals located?

CNS Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von CNS Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of CNS Pharmaceuticals from 9/30/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/30/2024.

When did CNS Pharmaceuticals pay the last dividend?

The last dividend was paid out on 9/30/2024.

What was the dividend of CNS Pharmaceuticals in the year 2023?

In the year 2023, CNS Pharmaceuticals distributed 0 USD as dividends.

In which currency does CNS Pharmaceuticals pay out the dividend?

The dividends of CNS Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von CNS Pharmaceuticals

Our stock analysis for CNS Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of CNS Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.